Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 risk-stratified treatment study for pediatric EBV-associated hemophagocytic lymphohistiocytosis
jRCTs041190053Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of prednisolone, etoposide and rituximab in Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis (EBV-HLH) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 1-year event-free survival in VP-16-treated patients. Started Jul 2019; status: completed.
02
Drugs
prednisoloneetoposiderituximab
03
Conditions
Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis (EBV-HLH)
Beyond the preview
Go deeper on jRCTs041190053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190053.